Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations

AI Ritchie, JA Wedzicha - Clinics in chest medicine, 2020 - chestmed.theclinics.com
Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are episodes of
symptom worsening 1 that have significant adverse consequences for patients. 2 The …

Treatment trials in young patients with chronic obstructive pulmonary disease and pre–chronic obstructive pulmonary disease patients: time to move forward

FJ Martinez, A Agusti, BR Celli, MLK Han… - American journal of …, 2022 - atsjournals.org
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and
cumulative gene–environment interactions over a lifetime. The evolving understanding of …

Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary

CF Vogelmeier, GJ Criner, FJ Martinez… - American journal of …, 2017 - atsjournals.org
This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …

[HTML][HTML] Lung-function trajectories leading to chronic obstructive pulmonary disease

P Lange, B Celli, A Agustí, G Boje Jensen… - … England Journal of …, 2015 - Mass Medical Soc
Background Chronic obstructive pulmonary disease (COPD) is thought to result from an
accelerated decline in forced expiratory volume in 1 second (FEV1) over time. Yet it is …

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel …

J Vestbo, A Papi, M Corradi, V Blazhko, I Montagna… - The Lancet, 2017 - thelancet.com
Background Limited data are available for the efficacy of triple therapy with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind …

D Singh, A Papi, M Corradi, I Pavlišová, I Montagna… - The Lancet, 2016 - thelancet.com
Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised …

J Vestbo, JA Anderson, RD Brook, PMA Calverley… - The Lancet, 2016 - thelancet.com
Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

J Vestbo, SS Hurd, AG Agustí, PW Jones… - American journal of …, 2013 - atsjournals.org
Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001,
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …

Comorbidities of COPD

A Cavaillès, G Brinchault-Rabin… - European …, 2013 - Eur Respiratory Soc
By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality.
Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco …

Inhaled corticosteroids in COPD: friend or foe?

A Agusti, LM Fabbri, D Singh, J Vestbo… - European …, 2018 - Eur Respiratory Soc
The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …